Big Gain For I-Mab

I-Mab (IMAB:NASDAQ) shot up at $0.96, a gain of 43%. On Mon, Apr 14, 2025, IMAB:NASDAQ touched a New 2-Week High of $0.96. The stock appeared on our News Catalysts scanner on Thu, Apr 03, 2025 at 06:43 PM in the 'INVESTOR UPDATE' category. From Mon, Mar 31, 2025, the stock recorded 20.00% Up Days and 45.45% Green Days

About I-Mab (IMAB:NASDAQ)

I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company's product pipeline includes TJ202, TJ301, TJ107, TJC4, TJD5, and TJM2.